CD19 and infection: However, the cumulative infection rate was significantly higher in the CAR‐T cell co‐therapy group (45.5% vs. 31.7%), probably because the anti‐CD19 therapy prolongs the recovery time of humoral immunity, increasing the risk of long‐term infection.34